ATLASATLAS fair value
ATLAS has no fair value for this stock today.
NRx Pharmaceuticals (NRXP)
NRx Pharmaceuticals stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$2.70▲ +5.88%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
47%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on NRx Pharmaceuticals in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On NRx Pharmaceuticals
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives NRx Pharmaceuticals a 47% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $2.38 and $2.99; in 9 out of 10, between $1.95 and $3.65. Estimated annual volatility is 56%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $126M
- 52-week high
- $5.06
- 52-week low
- $1.62
- Revenue (12 months)
- $3.4M
- Gross margin
- 58.8%
- Return on equity
- 179.6%
- Free cash flow (12 months)
- $-9.6M
- Beta
- 2.19
What this means
ATLAS does not publish a fair value for NRXP right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks NRXP has traded between $1.62 and $5.06. Today it is 46.6% below that high and 67% above its low.
Its beta is 2.19: it tends to move more than the market, both up and down.
About the company
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on severe depression, bipolar depression, post-traumatic stress disorder, and related suicidal ideation.
Want to see everything about NRx Pharmaceuticals?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does NRx Pharmaceuticals do?
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on severe depression, bipolar depression, post-traumatic stress disorder, and related suicidal ideation.
What is the chance NRXP goes up next month?
47%: close to a coin flip. In half of the simulated outcomes, NRXP ends the month between $2.38 and $2.99.
How big is NRx Pharmaceuticals and what is its P/E ratio?
NRx Pharmaceuticals's market capitalization is $126M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is NRXP?
ATLAS estimates annual volatility at 56%. In a typical month, half of the outcomes end between $2.38 and $2.99.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer